Environmental

ONCY appears to have limited direct environmental exposure as a clinical-stage oncology company, which is generally less carbon- and resource-intensive than manufacturing-heavy peers.

The provided metrics show no R&D intensity disclosure, limiting evidence of environmental process efficiency versus peers that report more detailed operational sustainability data.

Absence of disclosed environmental targets or emissions metrics constrains relative assessment, leaving ONCY broadly in line with smaller biotech peers but below transparent leaders.

Because environmental impact is mainly indirect through outsourced research and clinical operations, peer differentiation is likely modest unless supplier and trial-footprint controls are disclosed.

Social

ONCY’s social profile is shaped primarily by patient safety, trial ethics, and data integrity, where clinical-stage peers face similar obligations and scrutiny.

Limited public operating scale can reduce workforce and community exposure versus larger biotech peers, but it also leaves fewer disclosed social programs to compare.

No latest metrics provided on diversity, turnover, or clinical-trial outcomes, so relative positioning versus peers remains difficult to verify from available evidence.

As with many small biotechs, social risk is concentrated in trial conduct and communication quality, making governance of research processes the key differentiator versus peers.

Governance

The reported debt-to-equity ratio and net debt-to-EBITDA are not materially informative for governance, but they suggest limited balance-sheet complexity versus leveraged peers.

Zero disclosed stock-based compensation to revenue and R&D-to-revenue metrics reduce visibility into incentive alignment and capital allocation discipline relative to better-disclosed peers.

Small-cap biotech issuers often face weaker governance transparency than larger peers, and ONCY’s limited metric set constrains assessment of board oversight and controls.

Without filing-based evidence of board independence, audit quality, or shareholder-rights protections, ONCY cannot be placed above peers with stronger governance disclosure.

Overall Score

ONCY’s ESG positioning is broadly average for a small clinical-stage biotech, with limited environmental exposure offset by constrained disclosure and modest governance transparency versus peers.

Score Driver: Limited ESG Disclosure And Governance Transparency Relative To Better-Reporting Peers.